Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD 20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL)
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
10-2022
Journal Title
Leukemia Research
Department
Pediatrics
Recommended Citation
Chu, Y., Tian, M., Marcondes, M. Q., Overwijk, W., Lee, D. A., Klein, C., & Cairo, M. S. (2022). Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD 20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL). Leukemia Research, 121 (Suppl.), S27. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/770
COinS
